MicroGeneSys' VaxSyn HIV therapeutic vaccine
Executive Summary
The "disapproval notification period" for the Phase III trial of the gp160 vaccine has been extended for an additional six months following President Clinton's signing of the FY 1994 Defense Department appropriations bill on Nov. 11. The language agreed to in the funding bill's conference report, which passed both chambers Nov. 10, implements an amendment offered by Rep. Waxman (D-Calif.) Sept. 30 ("The Pink Sheet" Oct. 11, T&G-9). MicroGeneSys says Nov. 12 that it is "concerned that the recent congressional action will likely delay Phase III trials of gp160 in the United States.".
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth